UrokinaseThird Party Manufacturing in India

Urokinase is a naturally occurring enzyme that works by activating the body's own clot-dissolving system. It directly converts plasminogen, an inactive protein circulating in the blood, into plasmin, an active enzyme that breaks down fibrin. Fibrin is the structural protein that holds blood clots together, so by breaking it down, urokinase dissolves the clot and restores blood flow through the affected vessel. Unlike streptokinase, which is derived from bacteria and can cause allergic reactions, urokinase is of human origin and is non-antigenic, meaning it does not trigger an immune response. It acts directly on the clot rather than requiring a co-factor, making it a potent thrombolytic agent. Urokinase binds both to clot-bound plasminogen and to circulating plasminogen, which means it can work on existing clots while also preventing new ones from forming. The enzyme is produced naturally in the kidneys and is found in urine, which is how it was originally discovered. Therapeutically, it is manufactured through cell culture technology using human kidney cells to ensure consistent quality and potency. Its mechanism makes it effective for rapidly dissolving life-threatening clots in critical care settings.

Therapeutic Uses

Urokinase is prescribed for the treatment of:

• Pulmonary Embolism: Urokinase dissolves blood clots in the lungs that can be life-threatening, restoring normal blood flow and gas exchange.
• Deep Vein Thrombosis (DVT): Used to break up large clots in the deep veins of the legs or pelvis, reducing the risk of embolization.
• Myocardial Infarction (Heart Attack): Administered to dissolve coronary artery clots and restore blood flow to the heart muscle, limiting damage.
• Thrombosis of the Eye: Used for occlusions of retinal vessels to prevent vision loss.
• Catheter Clearance: Urokinase is also used to restore patency to occluded intravenous catheters and dialysis access lines.

Why Manufacturers Choose Urokinase

Urokinase is a vital thrombolytic enzyme with consistent demand from hospitals and critical care centers across India and export markets. As a biological product derived from human kidney cell cultures, it requires advanced bioprocessing capabilities that represent a significant manufacturing specialization. Indian pharmaceutical manufacturers with expertise in enzyme production and purification have a strategic advantage in this niche segment. Urokinase is typically supplied as a lyophilized powder in vials of 500,000 IU for reconstitution before intravenous administration. The growing incidence of cardiovascular diseases and thromboembolic disorders in India has driven sustained demand for thrombolytic agents. WHO-GMP certified manufacturing facilities are essential for producing this critical care biologic for both domestic use and regulated market exports.

This makes Urokinase one of the most sought-after molecules for third party manufacturing in India, with consistent demand from critical care units and export-oriented companies.